eflapegrastim eflapegrastim eflapegrastim, sold under the brand names rolvedon among others, is a long-acting g-csf analog developed by hanmi pharmaceutical and licensed to spectrum pharmaceuticals. eflapegrastim is a leukocyte growth factor. it is used to reduce the risk of febrile neutropenia in people with non-myeloid malignancies receiving myelosuppressive anti-cancer agents. eflapegrastimclinical datatrade namesrolvedonother nameseflapegrastim-xnst, hm-10460a, spi-2012license data us dailymed: eflapegrastim routes ofadministrationsubcutaneousatc codenonelegal statuslegal status us: ℞-only identifierscas number1384099-30-2chemspidernoneuniiut99ug9qjxkeggd11188 eflapegrastim was approved for medical use in the united states in september 2022. medical uses eflapegrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. its efficacy has been shown to be non-inferior to pegfilgrastim.